Concepedia

Sudeep Kundu

SK

13

Publications

2.8K

Citations

12

H-Index

1997

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

University of Lübeck

Probity Medical Research

Central Dermatology

The University of Melbourne

Sudeep Kundu is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and asthma.

Top concepts

Publications per year

1997–2023

13

Publications

13

Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction

Jonathan A. Leff, David S. Pearlman, Edwin A. Bronsky et al. · New England Journal of Medicine · 1998 · 555 citations · Full text

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Arun J. Sanyal, Edgar D. Charles, Brent A. Neuschwander‐Tetri et al. · The Lancet · 2018 · 511 citations

, , +7

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

Kim Papp, Kenneth B. Gordon, Diamant Thaçi et al. · New England Journal of Medicine · 2018 · 400 citations · Full text

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

April W. Armstrong, Melinda Gooderham, Richard B. Warren et al. · Journal of the American Academy of Dermatology · 2022 · 316 citations · Full text

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

Bruce Strober, Diamant Thaçi, Howard Sofen et al. · Journal of the American Academy of Dermatology · 2022 · 254 citations · Full text

Rows per page

1–5 of 13